三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

休市中 10-09 16:08:08

15.070

+0.080

+0.53%

最高15.230	最低14.910	成交量2,247万
今开15.050	昨收14.990	日振幅2.13%
总市值379.01亿	流通市值379.01亿	总股本25.15亿
成交额3.38亿	换手率0.89%	流通股本25.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":15.07,"timestamp":1791533288001,"preClose":14.99,"halted":0,"volume":22470468,"delay":0,"changeRate":0.005336891260840565,"floatShares":2515000000,"shares":2515000000,"eps":4.022274179243876,"marketStatus":"休市中","change":0.08,"latestTime":"10-09 16:08:08","open":15.05,"high":15.23,"low":14.91,"amount":338072441,"amplitude":0.021348,"askPrice":15.07,"askSize":4000,"bidPrice":15.05,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":3.8100282694701484,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":7,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":14.99,"dividendRate":0.016589,"openAndCloseTimeList":[[1791509400000,1791518400000],[1791522000000,1791532800000]],"volumeRatio":1.6583259112579727,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBI.HK","impliedVol":0.509,"impliedVolPercentile":0.3214},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2674856463","title":"汇添富基金管理股份有限公司减持三生制药(01530.HK)499.4万股 每股作价约15.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674856463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674856463?lang=zh_cn&edition=full","pubTime":"2026-10-09 19:10","pubTimestamp":1791544217,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","BK1593","BK1583","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674559278","title":"三生制药(01530)10月9日斥资3758.8万港元回购250万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674559278","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674559278?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:41","pubTimestamp":1791542518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，该公司于2026年10月9日斥资3758.8万港元回购250万股股份，每股回购价格为14.98-15.18港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1593","BK1583","BK1161","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114709376","title":"三生制药10月9日回购250万股，耗资约3,758.80万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114709376","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114709376?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:41","pubTimestamp":1791542516,"startTime":"0","endTime":"0","summary":"三生制药于2026年10月9日公告称，公司在香港联合交易所场内回购普通股250万股，占该次回购前公司已发行股本约0.1%。本次回购每股价格介乎14.98港元至15.18港元，合计耗资约3,758.80万港元。回购完成后，公司已发行股份总数减少至2,515,345,078股，库藏股数量相应增至22,976,000股。公告显示，本次股份回购基于公司于2026年6月25日通过的购回授权。相关授权允许公司最多回购253,707,141股，迄今公司已回购21,963,000股，占授权总数约0.87%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药10月9日回购250万股，耗资约3,758.80万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156842934","title":"三生制药10月8日回购170.00万股，耗资约2,650.00万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156842934","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156842934?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:26","pubTimestamp":1791455176,"startTime":"0","endTime":"0","summary":"三生制药于2026年10月8日发布公告，当日通过香港联交所场内回购普通股170.00万股，约占公司回购前已发行股本的0.07%。回购价格区间为每股15.40港元至15.75港元，合计耗资26,500,000港元。本次回购完成后，公司已发行股份总数减至2,517,845,078股，库藏股数增加至20,476,000股。截至公告日，公司可根据2026年6月25日通过的购回授权继续回购最多253,707,141股股份。公司明确表示，已遵守香港联合交易所有限公司证券上市规则及相关法例的规定。本次公告由公司秘书黎少娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药10月8日回购170.00万股，耗资约2,650.00万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673229075","title":"三生制药(01530)10月8日斥资2650万港元回购170万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673229075","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673229075?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:19","pubTimestamp":1791454775,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年10月8日该公司斥资2650万港元回购170万股，回购价格为每股15.4至15.75港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","01530","BK1583","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673734038","title":"创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673734038","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673734038?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:54","pubTimestamp":1791251688,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念普涨，截至发稿，歌礼制药-B 涨11.78%，再鼎医药涨6.55%，金斯瑞生物科技涨5.30%，晶泰控股涨4.40%，中国生物制药涨3.96%，三生制药涨3.41%，药明生物涨3.16%，康方生物涨3.11%，云顶新耀涨3.10%，四环医药涨2.82%。2026ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993103","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211977185.USD","KURE","IE00BPRC5H50.USD","LU2778985437.USD","01530","01952","00460","BK1141","LU1242518931.SGD","01672","LU0320764243.SGD","LU0348784397.USD","LU2476274308.USD","02228","06978","09688","LU0029874905.USD","LU0417516902.SGD","MEDX","HK0000306701.USD","LU0029874061.USD","BK4588","09926","01177","BK1521","ZLAB","01477","LNGR","LU0140636845.USD","IE00BZ08YT58.USD","LU0348827113.USD","LU0708995153.HKD","02269","LU0348766576.USD","159992","SG9999002463.SGD","LU0823426308.USD","01548","LU0320764599.SGD","LU0348735423.USD","LU0359201612.USD","IBBQ","BK1161","BK4139","BK1574","BK1191","LU0516422366.SGD","BK1515","LU0052750758.USD","LU0516423091.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157257950","title":"三生制药更新9月股份变动月报表，股本略增56,666股","url":"https://stock-news.laohu8.com/highlight/detail?id=1157257950","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157257950?lang=zh_cn&edition=full","pubTime":"2026-10-02 19:11","pubTimestamp":1790939488,"startTime":"0","endTime":"0","summary":"三生制药于2026年10月2日披露截至2026年9月30日的证券变动月报显示，公司法定股本未见变动，仍为500,000美元，对应50,000,000,000股普通股，每股面值为0.00001美元。截至9月末，普通股已发行股份为2,519,545,078股，库存股份为18,776,000股，合计2,538,321,078股。与上月底相比，已发行股份减少10,198,834股，库存股份增加10,255,500股，合计较8月底增长56,666股。同时，公司于2026年9月2日至9月29日期间，以每股15.162211-15.843853港元的价格回购股份共计10,255,500股，并将其列作库存股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193001984","title":"三生制药：花旗集团增持，好仓比例升至5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1193001984","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193001984?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:34","pubTimestamp":1790933689,"startTime":"0","endTime":"0","summary":"花旗集团于2026年9月25日因证券借贷池中持股比例增加而使其在三生制药（01530）的持股量增加约67.15万股，该笔变动无需支付代价，并非通过联交所公开市场直接买卖。花旗集团此次增持前持有三生制药好仓1.26亿股，占比4.99%；增持后持股量为1.27亿股，好仓比例升至5.02%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189221916","title":"异动解读｜三生制药盘中下跌5.61%，报15.58港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189221916","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189221916?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:51","pubTimestamp":1790905864,"startTime":"0","endTime":"0","summary":"10月2日，三生制药盘中下跌5.61%，报15.58港元/股，成交额4822.29万港元。三生制药所在的生物科技行业整体承压，个股中，百济神州跌6.92%，信达生物跌5.05%，康方生物跌4.42%，科伦博泰生物跌5.75%，荣昌生物跌8.24%。三生制药是一家主要从事生物制药产品开发、生产、市场推广及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物以及蔓迪、丽美治等小分子药物，同时开展CDMO业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671275129","title":"港股异动 | 三生制药(01530)涨超3% 旗下三生蔓迪携手德睿智药达成MDR-001独家合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2671275129","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671275129?lang=zh_cn&edition=full","pubTime":"2026-09-30 14:50","pubTimestamp":1790751052,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药涨超3%，截至发稿，涨3.54%，报32.74港元，成交额1543.68万港元。消息面上，据三生制药官微消息，9月28日，三生制药旗下子公司浙江三生蔓迪药业有限公司及万晟医药宣布，与杭州德睿智药科技有限公司就其自主研发的AI设计口服小分子GLP-1受体激动剂MDR-001，达成覆盖中国内地、中国香港及中国澳门的独家商业化合作。MDR-001目前正在中国开展针对成人肥胖或超重人群的Ⅲ期关键临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1593","KCAI","HK0000165453.HKD","BK1161","BK4588","VXUS","01530","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172136248","title":"三生制药：9月29日回购30万股，耗资约471万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172136248","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172136248?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:01","pubTimestamp":1790676080,"startTime":"0","endTime":"0","summary":"三生制药(01530)于2026年9月29日回购普通股30万股，约占该事件前公司已发行股本（不包括库藏股）总数的0.01%。本次回购价格为每股15.7港元，总金额约471万港元。回购完成后，公司已发行股份增至2,519,488,412股，库藏股增至18,776,000股。根据公告，回购授权于2026年6月25日通过，公司可回购股票的总数为253,707,141股，迄今已在交易所及其他交易所累计回购17,763,000股，占授权通过当日已发行股本总数的0.7%。\n公司确认，本次交易严格遵守了香港联合交易所有限公司证券上市规则及相关法例的要求，且在回购中并无重大变动。公告由公司秘书黎少娟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药：9月29日回购30万股，耗资约471万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670235746","title":"三生制药(01530)9月28日斥资2041万港元回购130万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670235746","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670235746?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:03","pubTimestamp":1790589820,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，该公司于2026年9月28日斥资2041万港元回购130万股股份，每股回购价格为15.6-15.8港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","BK1161","HELS","BK1593","BK1583","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172568926","title":"三生制药：9月28日回购130万股股份，总额约2,041.00万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172568926","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172568926?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:02","pubTimestamp":1790589739,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月28日发布翌日披露报表，公告当日通过香港联合交易所场内回购1,300,000股普通股股份，约占该公司已发行股本0.05%。每股回购价格介乎15.60港元至15.80港元，合计涉资20,410,000港元。回购完成后，公司已发行股份总数由2,521,088,412股变动为2,519,788,412股，库藏股数增至18,476,000股。三生制药方面确认，此次回购严格遵守香港联合交易所证券上市规则及相关法律法规，符合所有适用规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药：9月28日回购130万股股份，总额约2,041.00万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192995461","title":"异动解读｜三生制药盘中下跌5.06%，报16.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192995461","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192995461?lang=zh_cn&edition=full","pubTime":"2026-09-24 14:03","pubTimestamp":1790229829,"startTime":"0","endTime":"0","summary":"9月24日，三生制药盘中下跌5.06%，报16.15港元/股，成交额1.49亿港元。三生制药所在的生物科技行业整体承压，个股中，信达生物跌3.72%，康方生物跌4.26%，诺诚健华跌11.17%，百济神州跌1.92%，荣昌生物跌8.25%。三生制药是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司，主要产品包括特比澳、益比奥、益赛普等生物药物，同时开展CDMO业务，产品主要应用于血小板减少症、慢性肾病引起的贫血症等领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669548376","title":"三生“少帅”娄竞：从科学家到操盘手，是药二代更是创一代","url":"https://stock-news.laohu8.com/highlight/detail?id=2669548376","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669548376?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:02","pubTimestamp":1790164971,"startTime":"0","endTime":"0","summary":"三生官方资料将其列为益比奥、特比澳开发的领导科学家和主要研究员。2007年三生制药登陆纳斯达克，是国内较早赴美上市的生物药企之一。2015年三生回港上市，公司大事记称其当年成为全球生物制药领域受关注IPO之一。娄竞接手后先扩后收，早期保留赛普汀等肿瘤抗体，2020年前后逐步把资源收回到自身免疫。国健年报披露，相关款项三生国健占30%、沈阳三生占70%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1790134731525398876","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1583","BK1161","688336","HK0000165453.HKD","01530","BK1593","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669119340","title":"【券商聚焦】兴业证券维持三生制药（01530）增持评级 指核心经营质量改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2669119340","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669119340?lang=zh_cn&edition=full","pubTime":"2026-09-22 14:24","pubTimestamp":1790058242,"startTime":"0","endTime":"0","summary":"金吾财讯 | 兴业证券发布研报指，三生制药 发布2026年中期业绩公告。归母净利润下降主要受汇兑净损失等非经营性因素影响，经调整经营性归母净利率升至31.7%，核心经营质量持续改善。截至2026年8月，辉瑞已开展9项全球多中心临床试验，其中2项III期、3项II期和4项I期；SSGJ-707已注册11项研究，覆盖23个国家及地区，已启动1361家临床中心，预计入组5016例患者。2027年公司计划推动SSGJ-610提交NDA，多款产品有望获批上市。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992190","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01530","601377"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669549132","title":"港股午盘｜恒指涨0.56% 创新药概念股走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2669549132","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669549132?lang=zh_cn&edition=full","pubTime":"2026-09-21 12:04","pubTimestamp":1789963446,"startTime":"0","endTime":"0","summary":"恒指涨0.56%，恒生科技指数跌0.13%，创新药概念股走强，康方生物涨近9%，科伦博泰生物涨近8%，三生制药涨逾6%。黄金股普跌，中国黄金国际跌逾7%，灵宝黄金跌近5%，山东黄金、紫金黄金国际跌逾3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202609213879859453.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202609213879859453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348735423.USD","01787","LU0540923850.HKD","LU2279858448.HKD","HK0000500386.USD","LU0196878994.USD","BK1592","LU0828237940.HKD","LU1328277881.USD","SG9999003461.SGD","09115","HK0000252152.HKD","LU0348784397.USD","03419","LU2488822045.USD","LU2039709279.SGD","KURE","03330","MHImain","LU0348766576.USD","SG9999001093.SGD","LU0979878070.USD","BK1161","83115","LU1720050803.USD","LU0181495838.USD","LU0417516738.SGD","LU1171460220.USD","LU0140636845.USD","LU1831875114.USD","LU0593848301.USD","02259","HHImain","06990","BK1583","BK1574","LU2778985437.USD","LU2543165471.USD","LU0244354667.USD","01530","BK1198","IE00B5MMRT66.SGD","02833","BK1544","02800","LU0634319403.HKD","LU0348783233.USD","07500","IE00BPRC5H50.USD","LU1961090484.USD","LU2213484517.USD","LU1188198961.HKD","LU2399975544.HKD","LU1794554557.SGD","02099","SGXZ62798434.SGD","HSI","82800","07300","LU0417516902.SGD","JINFF","LU1813983027.USD","LU0463099449.HKD","LU0348827113.USD","LU0348767384.USD","SGXZ86797644.SGD","513600","LU0348825331.USD","LU0417516571.SGD","LU0326950275.SGD","09926","MCHmain","03115","HK0000252160.HKD","LU1242518857.USD","IE00B543WZ88.USD","07200","LU0314109678.HKD","03037","600547","HSTECH","HK0000165453.HKD","LU2476274308.USD","BK1593","LU0561508036.HKD","LU2476274720.SGD","LU1242518931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669509139","title":"医美概念股多股上扬 三生制药（01530）涨5.71%、四环医药（00460）涨4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669509139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669509139?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:09","pubTimestamp":1789956581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股多股上扬，截至发稿，山东新华制药股份 涨10.81%，三生制药涨5.71%，四环医药涨4.17%，昊海生物科技涨3.82%，复星医药涨3.12%，现代牙科涨3.10%，时代天使涨2.25%。消息面上，国金证券表示，医美板块下游连锁景气回暖，上游平台化逻辑有望兑现，建议关注上游头部连锁化机构、需求扩容下具备强渠道能力的上游平台化标的。看好布局差异化赛道的上游医美产品厂商及满足医美新场景需求的下游医美机构。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1191","BK1587","01530","BK1100","06826","BK1583","HK0000165453.HKD","00460","03600","02196","06699","BK1593","00719","BK1600","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127607565","title":"异动解读｜三生制药盘中上涨5.21%，持续回购叠加机构增持提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1127607565","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127607565?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:45","pubTimestamp":1789955151,"startTime":"0","endTime":"0","summary":"9月21日，三生制药盘中上涨5.21%，报16.57港元，成交额8596.13万港元。消息面上，公司近期持续大手笔回购股份，仅9月以来已累计实施6次回购，合计回购约865.55万股，耗资约1.36亿港元。今年以来公司已合计回购9次，累计金额约2.71亿港元，彰显管理层对公司价值的信心。此外，公司董事长娄竞于9月7日以每股16.0港元增持49万股，贝莱德亦于近期增持约4760万股，机构与管理层同步加仓形成共振。公司核心品种SSGJ-707与辉瑞的全球临床推进被视为主要上行催化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药盘中上涨，回购与增持共振","news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146270840","title":"三生制药：9月18日回购106.55万股，耗资约1,688.16万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146270840","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146270840?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:21","pubTimestamp":1789726867,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月18日公告称，公司于当日在香港联交所场内回购普通股1,065,500股，约占此前已发行股份总数的0.04%。本次回购价格区间为每股15.75港元至15.90港元，合计金额为16,881,625港元，折合约1,688.16万港元。另根据公告，本次回购后，公司将于2026年10月18日前暂停发行新股及出售或转让任何库存股份。公司在公告中表示，已遵守香港联合交易所有限公司证券上市规则及相关法律规定。本次回购事项的公告由公司秘书黎少娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药：9月18日回购106.55万股，耗资约1,688.16万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.0492},{"period":"1month","weight":-0.0669},{"period":"3month","weight":-0.1537},{"period":"6month","weight":-0.334},{"period":"1year","weight":-0.4657},{"period":"ytd","weight":-0.3676}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":-0.0421},{"period":"3month","weight":0.0015},{"period":"6month","weight":-0.065},{"period":"1year","weight":-0.095},{"period":"ytd","weight":-0.0554}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006634},{"month":2,"riseRate":0.454545,"avgChangeRate":0.001777},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113184},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.080953},{"month":6,"riseRate":0.727273,"avgChangeRate":0.025359},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.034677},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.015863},{"month":9,"riseRate":0.666667,"avgChangeRate":0.027514},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.024335},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059928},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045348}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}